Join our daily newsletter At The Bell to receive exclusive market insights
- Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in Melbourne
- This trial will build on the existing data that confirms Rhinoswab is a superior method for sampling upper respiratory diseases such as SARS-CoV-2 (COVID-19) and influenza A and B
- The Rhinoswab is a novel sampling technology that improves the sample collection process
- It can be self administered, which RNO says makes sampling easier, more acceptable and more comfortable than traditional methods
- Rhinomed ended the day 1.61 per cent in the red with shares trading at 30.5 cents
Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in Melbourne.
This trial will build on the existing data that confirms Rhinoswab is a superior method for sampling upper respiratory diseases such as SARS-CoV-2 (COVID-19) and influenza A and B.
It will determine if users consider Rhinoswab more comfortable and convenient for sample collection and compare the sensitivity, specify and other measurement of the Rhinoswab compared to the traditional swab and saliva methods.
The trial will recruit 250 people and will be conducted over 30 to 50 days.
The Rhinoswab is a novel sampling technology that improves the sample collection process.
It can be self administered, which RNO said makes sampling easier, more acceptable and more comfortable than traditional methods.
CEO Michael Johnson commented on the trial.
“SARS-CoV-2 testing will be a part of our lives for some time to come. The Rhinoswab provides an easier, more standardised and comfortable sample collection method to encourage people to get tested, more often,” Mr Johnson said.
“There is clear evidence that vaccination and mass high frequency testing are the key tools we can use to keep our community safe – not just from SARS-CoV-2 but from all upper respiratory diseases including RSV and Influenza.”
“The Rhinoswab is a more effective and preferred method for testing people.”
Rhinomed has ended the day 1.61 per cent in the red with shares trading at 30.5 cents in a $77.41 million market cap.
